| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 39 | 2024 | 563 | 11.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2021 | 367 | 6.510 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 11 | 2021 | 33 | 4.980 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 309 | 3.830 |
Why?
|
| Immunoconjugates | 5 | 2024 | 17 | 3.260 |
Why?
|
| Fallopian Tube Neoplasms | 8 | 2020 | 49 | 3.220 |
Why?
|
| Indazoles | 5 | 2020 | 16 | 3.180 |
Why?
|
| Piperidines | 5 | 2020 | 42 | 3.110 |
Why?
|
| Uterine Cervical Neoplasms | 14 | 2020 | 277 | 3.100 |
Why?
|
| Phthalazines | 7 | 2021 | 22 | 3.010 |
Why?
|
| Piperazines | 6 | 2021 | 45 | 2.780 |
Why?
|
| Peritoneal Neoplasms | 6 | 2020 | 76 | 2.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2024 | 131 | 2.340 |
Why?
|
| Clinical Trials as Topic | 7 | 2024 | 205 | 2.140 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 657 | 2.130 |
Why?
|
| Female | 72 | 2024 | 14466 | 2.120 |
Why?
|
| Middle Aged | 47 | 2024 | 6820 | 1.910 |
Why?
|
| Maytansine | 3 | 2024 | 4 | 1.860 |
Why?
|
| Endometrial Neoplasms | 9 | 2018 | 184 | 1.850 |
Why?
|
| Aged | 40 | 2024 | 5168 | 1.840 |
Why?
|
| Humans | 80 | 2024 | 26846 | 1.750 |
Why?
|
| Carboplatin | 10 | 2021 | 106 | 1.620 |
Why?
|
| Chemoradiotherapy | 5 | 2019 | 41 | 1.590 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 1928 | 1.580 |
Why?
|
| Folate Receptor 1 | 2 | 2024 | 10 | 1.570 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 104 | 1.510 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2018 | 39 | 1.480 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 21 | 1.370 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2018 | 67 | 1.360 |
Why?
|
| Paclitaxel | 10 | 2021 | 183 | 1.350 |
Why?
|
| Neoplasms | 6 | 2022 | 756 | 1.280 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2019 | 228 | 1.210 |
Why?
|
| Adult | 32 | 2024 | 7384 | 1.190 |
Why?
|
| Genital Neoplasms, Female | 3 | 2020 | 61 | 1.170 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2017 | 31 | 0.980 |
Why?
|
| Patient Selection | 2 | 2017 | 143 | 0.970 |
Why?
|
| Retrospective Studies | 25 | 2024 | 2433 | 0.970 |
Why?
|
| Biomarkers, Tumor | 6 | 2022 | 377 | 0.960 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 14 | 0.930 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 456 | 0.890 |
Why?
|
| Cisplatin | 6 | 2019 | 172 | 0.860 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 6 | 0.820 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 124 | 0.810 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 225 | 0.780 |
Why?
|
| Angiopoietin-2 | 2 | 2019 | 10 | 0.780 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 32 | 0.780 |
Why?
|
| Platinum | 1 | 2021 | 17 | 0.780 |
Why?
|
| Angiopoietin-1 | 2 | 2019 | 8 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2021 | 146 | 0.770 |
Why?
|
| Cardiotoxicity | 2 | 2019 | 4 | 0.760 |
Why?
|
| Oligopeptides | 1 | 2021 | 95 | 0.730 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 143 | 0.720 |
Why?
|
| Lymph Nodes | 6 | 2020 | 95 | 0.710 |
Why?
|
| Benzodiazepines | 1 | 2020 | 10 | 0.710 |
Why?
|
| Pyrroles | 1 | 2020 | 35 | 0.700 |
Why?
|
| Treatment Outcome | 15 | 2020 | 2264 | 0.700 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 586 | 0.690 |
Why?
|
| Pyrazoles | 4 | 2021 | 62 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 98 | 0.670 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2019 | 4 | 0.660 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2022 | 107 | 0.650 |
Why?
|
| Long QT Syndrome | 1 | 2019 | 12 | 0.640 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 57 | 0.640 |
Why?
|
| Mutation | 6 | 2021 | 820 | 0.630 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 77 | 0.630 |
Why?
|
| Tablets | 1 | 2018 | 6 | 0.610 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 144 | 0.600 |
Why?
|
| Bevacizumab | 5 | 2021 | 93 | 0.590 |
Why?
|
| Dietary Fats | 1 | 2018 | 55 | 0.580 |
Why?
|
| BRCA2 Protein | 4 | 2021 | 18 | 0.580 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2008 | 35 | 0.580 |
Why?
|
| BRCA1 Protein | 4 | 2021 | 23 | 0.580 |
Why?
|
| Hyperinsulinism | 1 | 2017 | 15 | 0.560 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 14 | 0.560 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 31 | 0.550 |
Why?
|
| Double-Blind Method | 5 | 2021 | 399 | 0.540 |
Why?
|
| Precision Medicine | 1 | 2015 | 67 | 0.490 |
Why?
|
| Prognosis | 6 | 2020 | 759 | 0.470 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 16 | 0.460 |
Why?
|
| Quinolines | 1 | 2014 | 25 | 0.460 |
Why?
|
| Young Adult | 7 | 2024 | 2582 | 0.450 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 442 | 0.430 |
Why?
|
| Cohort Studies | 5 | 2019 | 859 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 152 | 0.420 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2021 | 5 | 0.400 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 107 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 465 | 0.370 |
Why?
|
| Pyrimidinones | 2 | 2021 | 15 | 0.370 |
Why?
|
| Obesity | 1 | 2017 | 650 | 0.370 |
Why?
|
| Salvage Therapy | 1 | 2010 | 32 | 0.360 |
Why?
|
| Organoplatinum Compounds | 3 | 2021 | 23 | 0.350 |
Why?
|
| Pyrazines | 2 | 2021 | 23 | 0.350 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 31 | 0.330 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 67 | 0.330 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 30 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 357 | 0.320 |
Why?
|
| Thrombocytopenia | 3 | 2020 | 113 | 0.310 |
Why?
|
| Peritoneum | 1 | 2008 | 7 | 0.300 |
Why?
|
| Lymph Node Excision | 5 | 2016 | 94 | 0.300 |
Why?
|
| Age Factors | 3 | 2017 | 716 | 0.300 |
Why?
|
| Cervical Intraepithelial Neoplasia | 2 | 2007 | 80 | 0.300 |
Why?
|
| Vesicovaginal Fistula | 1 | 2007 | 4 | 0.290 |
Why?
|
| Medical Oncology | 2 | 2020 | 85 | 0.280 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 119 | 0.280 |
Why?
|
| Abdominal Fat | 2 | 2017 | 17 | 0.280 |
Why?
|
| Uterine Neoplasms | 1 | 2007 | 70 | 0.280 |
Why?
|
| Incidence | 2 | 2018 | 545 | 0.270 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 284 | 0.270 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2016 | 17 | 0.260 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 218 | 0.250 |
Why?
|
| Electrocardiography | 2 | 2019 | 391 | 0.240 |
Why?
|
| Adolescent | 4 | 2019 | 2957 | 0.230 |
Why?
|
| Survival Rate | 4 | 2015 | 406 | 0.230 |
Why?
|
| United States | 2 | 2020 | 2032 | 0.220 |
Why?
|
| Taxoids | 2 | 2017 | 36 | 0.210 |
Why?
|
| Area Under Curve | 3 | 2018 | 94 | 0.210 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 288 | 0.200 |
Why?
|
| Nausea | 2 | 2019 | 16 | 0.200 |
Why?
|
| Homologous Recombination | 1 | 2022 | 9 | 0.200 |
Why?
|
| Fallopian Tubes | 1 | 2021 | 14 | 0.190 |
Why?
|
| Fatigue | 2 | 2019 | 57 | 0.190 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 30 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 189 | 0.190 |
Why?
|
| Time Factors | 2 | 2019 | 1562 | 0.190 |
Why?
|
| DNA Damage | 2 | 2019 | 149 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 17 | 0.180 |
Why?
|
| Dipeptidases | 1 | 2020 | 5 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2014 | 163 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 108 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 38 | 0.170 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2019 | 4 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 5 | 0.170 |
Why?
|
| Injections, Intraperitoneal | 1 | 2019 | 34 | 0.170 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 65 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2022 | 246 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2019 | 29 | 0.170 |
Why?
|
| Tumor Burden | 1 | 2019 | 108 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2020 | 250 | 0.160 |
Why?
|
| Canada | 1 | 2019 | 58 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 52 | 0.160 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 9 | 0.160 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 11 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 54 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 74 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2019 | 276 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 166 | 0.160 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Diarrhea | 1 | 2018 | 53 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 2018 | 3 | 0.150 |
Why?
|
| Food-Drug Interactions | 1 | 2018 | 3 | 0.150 |
Why?
|
| Prodrugs | 1 | 2018 | 29 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2018 | 34 | 0.150 |
Why?
|
| Fasting | 1 | 2018 | 77 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.140 |
Why?
|
| Ascitic Fluid | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 60 | 0.140 |
Why?
|
| Platinum Compounds | 1 | 2017 | 13 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2016 | 1216 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 17 | 0.140 |
Why?
|
| Age of Onset | 1 | 2017 | 68 | 0.140 |
Why?
|
| Glycolysis | 1 | 2017 | 82 | 0.140 |
Why?
|
| Neutropenia | 1 | 2017 | 35 | 0.140 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 54 | 0.140 |
Why?
|
| Life Style | 1 | 2017 | 83 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2016 | 22 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 238 | 0.130 |
Why?
|
| Health Care Reform | 1 | 2016 | 13 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 52 | 0.130 |
Why?
|
| Brachytherapy | 1 | 2016 | 46 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2019 | 74 | 0.130 |
Why?
|
| Gynecology | 1 | 2016 | 55 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2016 | 53 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 90 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 10 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 58 | 0.120 |
Why?
|
| Diet | 1 | 2017 | 223 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 544 | 0.120 |
Why?
|
| Cyclophosphamide | 2 | 2019 | 38 | 0.120 |
Why?
|
| Aorta, Abdominal | 1 | 2014 | 15 | 0.110 |
Why?
|
| Action Potentials | 1 | 2014 | 194 | 0.110 |
Why?
|
| Recurrence | 2 | 2013 | 316 | 0.110 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2013 | 11 | 0.110 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 29 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2015 | 203 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2013 | 17 | 0.110 |
Why?
|
| Biomarkers | 1 | 2016 | 733 | 0.110 |
Why?
|
| Animals | 4 | 2019 | 9962 | 0.110 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 17 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 2014 | 270 | 0.100 |
Why?
|
| Cetuximab | 1 | 2012 | 20 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 58 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 464 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 374 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 247 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2014 | 587 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 980 | 0.090 |
Why?
|
| Male | 5 | 2020 | 12874 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 18 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 316 | 0.090 |
Why?
|
| Colposcopy | 2 | 2007 | 61 | 0.090 |
Why?
|
| Oklahoma | 1 | 2014 | 973 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 1263 | 0.090 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 57 | 0.080 |
Why?
|
| Hysterectomy | 2 | 2013 | 80 | 0.080 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 28 | 0.080 |
Why?
|
| Weight Loss | 1 | 2009 | 72 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2007 | 702 | 0.080 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 33 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 251 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 49 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 83 | 0.070 |
Why?
|
| Bridged-Ring Compounds | 1 | 2007 | 18 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2019 | 313 | 0.070 |
Why?
|
| Conization | 1 | 2007 | 9 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 44 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 151 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 200 | 0.070 |
Why?
|
| Comorbidity | 1 | 2008 | 252 | 0.070 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 2007 | 63 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2005 | 143 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 472 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 508 | 0.070 |
Why?
|
| Prevalence | 1 | 2007 | 472 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 137 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2007 | 386 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 104 | 0.060 |
Why?
|
| Laser Coagulation | 1 | 2003 | 13 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2008 | 604 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 69 | 0.050 |
Why?
|
| Forecasting | 1 | 2022 | 71 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 63 | 0.050 |
Why?
|
| Placebos | 1 | 2021 | 45 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 50 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2022 | 64 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 116 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2020 | 6 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 25 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 34 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 231 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 19 | 0.040 |
Why?
|
| Pelvis | 1 | 2019 | 37 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 36 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 39 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 4406 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 203 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 419 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 93 | 0.040 |
Why?
|
| Epothilones | 1 | 2018 | 5 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2018 | 7 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 114 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2018 | 16 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 30 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2018 | 24 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 100 | 0.040 |
Why?
|
| Sirolimus | 1 | 2018 | 68 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 26 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2017 | 19 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 16 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 59 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 20 | 0.040 |
Why?
|
| Abdomen | 1 | 2017 | 41 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 139 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 135 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 771 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 231 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 453 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 144 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 439 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 187 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 390 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2015 | 12 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 15 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 397 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 667 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 85 | 0.030 |
Why?
|
| Apoptosis | 1 | 2017 | 739 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 60 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 180 | 0.030 |
Why?
|
| Omentum | 1 | 2005 | 4 | 0.020 |
Why?
|
| Laparotomy | 1 | 2005 | 29 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 52 | 0.020 |
Why?
|
| Carcinoma | 1 | 2005 | 71 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 215 | 0.010 |
Why?
|